When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
IMV - IMV doses first patient in phase 1b trial of MVP-S in patients with breast cancer
IMV Inc.
IMV (NASDAQ:IMV) said the first patient with hormone receptor positive/HER2-negative (HR+/HER2-) breast cancer was dosed with its lead compound maveropepimut-S ((MVP-S, formerly known as DPX-Survivac)). In the phase 1b trial, MVP-S is being administered in combination with an aromatase inhibitor, with or without radiotherapy or cyclophosphamide prior to surgery.